Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Biol Blood Marrow Transplant. 2013 Jan;19(1):156-60. doi: 10.1016/j.bbmt.2012.09.004. Epub 2012 Sep 16.
Single-donor dominance is observed in the majority of patients following double-unit cord blood transplantation (dCBT); however, the biological basis for this outcome is poorly understood. To investigate the possible influence of specific cell lineages on dominance in dCBT, flow cytometry assessment for CD34(+), CD14(+), CD20(+), CD3(-)CD56(+), CD3(+)CD56(+) (natural killer), and T cell subsets (CD4(+), CD8(+), memory, naïve, and regulatory) was performed on individual units. Subsets were calculated as infused viable cells per kilogram of recipient actual weight. Sixty patients who underwent dCBT were included in the final analysis. Higher CD3(+) cell dose was statistically concordant with the dominant unit in 72% of cases (P = .0006). Further T cell subset analyses showed that dominance was correlated more with the naive CD8(+) cell subset (71% concordance; P = .009) than with the naive CD4(+) cell subset (61% concordance; P = .19). These data indicate that a greater total CD3(+) cell dose, particularly of naïve CD3(+)CD8(+) T cells, may play an important role in determining single-donor dominance after dCBT.
在大多数接受双份脐血移植（dCBT）的患者中观察到单个供体优势；然而，这种结果的生物学基础尚不清楚。为了研究特定细胞谱系对 dCBT 中优势的可能影响，对单个单位进行了 CD34(+)、CD14(+)、CD20(+)、CD3(-)CD56(+)、CD3(+)CD56(+)（自然杀伤）和 T 细胞亚群（CD4(+)、CD8(+)、记忆、幼稚和调节）的流式细胞术评估。亚群按输注给受者实际体重每公斤的有活力细胞计算。最终分析纳入了 60 名接受 dCBT 的患者。在 72%的病例中，较高的 CD3(+)细胞剂量与优势单位具有统计学一致性（P =.0006）。进一步的 T 细胞亚群分析表明，优势与幼稚 CD8(+)细胞亚群更相关（71%一致性；P =.009），而与幼稚 CD4(+)细胞亚群（61%一致性；P =.19）更相关。这些数据表明，更大的总 CD3(+)细胞剂量，特别是幼稚的 CD3(+)CD8(+)T 细胞，可能在确定 dCBT 后单个供体优势中发挥重要作用。
